Stake Purchase • Medical Products

Donaldson Invests In Medica

On April 29, 2024, Donaldson invested in medical products company Medica

Investment Context

This is Donaldson’s 1st transaction in the Medical Products sector.
This is Donaldson’s 2nd transaction in Italy.

Explore All 129 Stake Purchase Medical Products Deals - Search the Database Free

Investment Summary
Date	April 29, 2024
Target	Medica
Sector	Medical Products
Investor(s)	Donaldson
Deal Type	Stake Purchase

Target Company

Medica

Medolla, Italy

Medica provides hollow fiber membrane filtration technology for medical device applications and water purification. The company's hollow fiber membrane filtration products are used for blood purification in numerous applications including dialysis, continuous renal replacement therapies (CRRT), and therapeutic apheresis. Medica was formed in 1985 and is based in Medolla, Italy.

Explore More Deals

Browse All 215,156 Deals

FILTER BY

Buyer Type (PE or Strategic)
Deal Size ($10M to $10B+)
Sector (60 Sectors)
Deal Type
Geography
& More

Search Free

Investor Overview 1

Investor

Donaldson

Bloomington, Minnesota, United States

Category	Company
Founded	1915
Sector	Machinery
Employees	14,000
Revenue	3.6B USD (2024)

DESCRIPTION

Donaldson's corporate headquarters in Minneapolis, Minnesota.

Donaldson is a provider of filtration systems and replacement parts. Donaldson is a technology-driven company committed to satisfying customer needs for filtration solutions through innovative research and development. Donaldson was incorporated in 1915 and is based in Bloomington, Minnesota.

Deal Context for Investor	#
Overall	17 of 17
Sector: Medical Products	1 of 1
Type: Stake Purchase	2 of 2
Country: Italy	2 of 2
Year: 2024	1 of 1

PREVIOUS DEAL

DATE	TARGET	DEAL TYPE	VALUE
2023-06-29	Univercells Nivelles, Belgium Univercells is a producer of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing. The Company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells is based in Nivelles, Belgium.	Buy	-

DATE

TARGET

DEAL TYPE

VALUE

2023-06-29

Univercells

Nivelles, Belgium

Univercells is a producer of innovative biomanufacturing solutions for cell and gene therapy research, development and commercial manufacturing. The Company offers a comprehensive technology portfolio leveraging the strengths of process intensification and chaining as a direct answer to the growing demand of viral vectors and viral vaccines. Univercells is based in Nivelles, Belgium.

Buy

Explore Related M&A Activity

Medical Products M&A - Stake Purchase M&A Deals - Italy M&A - 2024 M&A